Literature DB >> 3510772

Effects of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure.

E H Sonnenblick, R Grose, J Strain, A A Zelcer, T H LeJemtel.   

Abstract

The potent vasodilating properties of the bipyridine derivatives confounds the assessment of changes in contractility as measured by peak positive left ventricular dP/dt and explains why the positive inotropic action of these agents has not been consistently demonstrated in patients with ventricular dysfunction. Therefore we studied the individual dose-response effects of intravenous milrinone on myocardial contractility as measured by peak positive left ventricular dP/dt in the context of concurrent changes in ventricular filling pressure. Incremental doses of milrinone caused a dose-related increase in peak positive left ventricular dP/dt in six of 11 patients. Peak positive left ventricular dP/dt was unchanged in four patients and reduced in one patient, all of whom experienced a substantial fall in left ventricular filling pressure. Thus milrinone has a definite inotropic effect in addition to its potent vasodilating properties.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3510772

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

Review 1.  Phosphodiesterase inhibition by new cardiotonic agents: mechanism of action and possible clinical relevance in the therapy of congestive heart failure.

Authors:  H von der Leyen
Journal:  Klin Wochenschr       Date:  1989-06-15

2.  The positive inotropic response to milrinone in isolated human and guinea pig myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-10       Impact factor: 3.000

Review 3.  Milrinone. A preliminary review of its pharmacological properties and therapeutic use.

Authors:  R A Young; A Ward
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 4.  Use of milrinone in cardiac surgical patients.

Authors:  K M Sherry; T J Locke
Journal:  Cardiovasc Drugs Ther       Date:  1993-08       Impact factor: 3.727

Review 5.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.